Cargando…

Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults

Haemagglutination inhibition (HI) and neutralization (NT) titers as well as haemagglutinin (HA) specific antibody responses were examined in 50 healthy adults aged between 22 and 69 y old after two intranasal administrations of an inactivated whole virus vaccine derived from A/Victoria/210/2009 viru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ainai, Akira, Tamura, Shin-ichi, Suzuki, Tadaki, van Riet, Elly, Ito, Ryo, Odagiri, Takato, Tashiro, Masato, Kurata, Takeshi, Hasegawa, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906363/ https://www.ncbi.nlm.nih.gov/pubmed/23896606 http://dx.doi.org/10.4161/hv.25458

Ejemplares similares

Human immune responses elicited by an intranasal inactivated H5 influenza vaccine
por: Ainai, Akira, et al.
Publicado: (2020)

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
por: Hasegawa, Hideki, et al.
Publicado: (2009)

Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
por: Tazaki, Taiyu, et al.
Publicado: (2018)

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan
por: Ainai, Akira, et al.
Publicado: (2015)

Identification of the properties of H5 influenza vaccine viruses with high hemagglutinin yields
por: Arita, Tomoko, et al.
Publicado: (2023)

Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells
por: Suzuki, Yasushi, et al.
Publicado: (2016)

Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
por: Hemmi, Takuya, et al.
Publicado: (2022)

cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue
por: Takaki, Hiromi, et al.
Publicado: (2017)

Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection
por: Kawaguchi, Akira, et al.
Publicado: (2017)

An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection
por: van der Ley, Peter A., et al.
Publicado: (2021)

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice
por: Hua, Tao, et al.
Publicado: (2022)

The effects of smoking and smoking cessation on nasal mucociliary clearance, mucus properties and inflammation
por: Utiyama, Daniela Mitiyo Odagiri, et al.
Publicado: (2016)

The administration of intranasal live attenuated influenza vaccine induces changes in the nasal microbiota and nasal epithelium gene expression profiles
por: Tarabichi, Y., et al.
Publicado: (2015)

Suitability of Polymyxin B as a Mucosal Adjuvant for Intranasal Influenza and COVID-19 Vaccines
por: Yoshino, Naoto, et al.
Publicado: (2023)

Comparison of suspension MDCK cells, adherent MDCK cells, and LLC‐MK2 cells for selective isolation of influenza viruses to be used as vaccine seeds
por: Harada, Yuichi, et al.
Publicado: (2019)

Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
por: Potter, C. W., et al.
Publicado: (1975)

Strategies for intranasal delivery of vaccines
por: Zaman, Mehfuz, et al.
Publicado: (2012)

Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs
por: Dhakal, Santosh, et al.
Publicado: (2018)

Invaplex functions as an intranasal adjuvant for subunit and DNA vaccines co-delivered in the nasal cavity of nonhuman primates
por: Camp, Jeremy V., et al.
Publicado: (2021)

Application of spatial transcriptomics analysis using the Visium system for the mouse nasal cavity after intranasal vaccination
por: Toyama, Sakiko, et al.
Publicado: (2023)

Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses
por: Raeven, René H. M., et al.
Publicado: (2020)

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
por: Tarride, Jean-Eric, et al.
Publicado: (2012)

Nasal mucus proteome and its involvement in allergic rhinitis
por: Tomazic, Peter Valentin, et al.
Publicado: (2020)

A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2022)

Cytokines: The Future of Intranasal Vaccine Adjuvants
por: Thompson, Afton L., et al.
Publicado: (2011)

A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease
por: Lindell, Dennis M., et al.
Publicado: (2011)

Bovine Respiratory Disease Vaccination Against Viral Pathogens: Modified-Live Versus Inactivated Antigen Vaccines, Intranasal Versus Parenteral, What Is the Evidence?
por: Chamorro, Manuel F., et al.
Publicado: (2020)

Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination
por: Nantachit, Nattika, et al.
Publicado: (2016)

Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models
por: Zhou, Runhong, et al.
Publicado: (2021)

Intranasal COVID-19 vaccine: a modern vaccination approach
por: Shahnoor, Syeda, et al.
Publicado: (2023)

The (potential) role of apolipoproteins in nasal mucus of allergic rhinitis patients
por: Tomazic, Peter, et al.
Publicado: (2014)

IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination
por: Kobari, Shingo, et al.
Publicado: (2020)

An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody
por: Sano, Kaori, et al.
Publicado: (2021)

Characterization of neuraminidase inhibitor‐resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post‐pandemic periods in Japan
por: Takashita, Emi, et al.
Publicado: (2013)

Advantages of Intranasal Vaccination and Considerations on Device Selection
por: Birkhoff, M., et al.
Publicado: (2009)

A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice
por: Tokunoh, Nagisa, et al.
Publicado: (2023)

Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response
por: Tzeng, Stephany Y., et al.
Publicado: (2018)

A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines
por: Wada, Yamato, et al.
Publicado: (2017)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody
por: Saito, Shinji, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4c7ghf5js29986c2fg0tbbp47h